Literature DB >> 32944132

Novel Cyclic Tetramer Compounds as PCSK9 Inhibitors for Treating Metabolic Disorders.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2020        PMID： 32944132      PMCID： PMC7488278          DOI： 10.1021/acsmedchemlett.0c00388

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar.

Authors:  David Preiss; Jonathan A Tobert; G Kees Hovingh; Christina Reith
Journal:  J Am Coll Cardiol       Date:  2020-04-28       Impact factor: 24.094

Review 2.  The PCSK9 revolution: Current status, controversies, and future directions.

Authors:  Bruce A Warden; Sergio Fazio; Michael D Shapiro
Journal:  Trends Cardiovasc Med       Date:  2019-05-21       Impact factor: 6.677

Review 3.  Statins and PCSK9 inhibitors: A new lipid-lowering therapy.

Authors:  Enrique Gallego-Colon; Aner Daum; Chaim Yosefy
Journal:  Eur J Pharmacol       Date:  2020-04-14       Impact factor: 4.432

Review 4.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease.

Authors:  Mohammad Alkhalil
Journal:  Curr Drug Metab       Date:  2019       Impact factor: 3.731
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.